Renalytix AI plc develops artificial intelligence (AI) enabled clinical decision support solutions for kidney disease. It is developing KidneyIntelX, an AI-enabled, clinical-laboratory based solution that supports physician decision making by improving identification, prediction, and risk stratification of patients with kidney disease. The company is based in Cardiff, the United Kingdom. Renalytix AI plc (AIM:RENX) operates independently of EKF Diagnostics Holdings plc as of November 2, 2018.
Industry, Sector and Symbol
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
CIKN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Renalytix Ai (LON:RENX) Frequently Asked Questions
What is Renalytix Ai's stock symbol?
Renalytix Ai trades on the London Stock Exchange (LON) under the ticker symbol "RENX."
Has Renalytix Ai been receiving favorable news coverage?
Media stories about RENX stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Renalytix Ai earned a news sentiment score of 0.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Renalytix Ai.
Who are some of Renalytix Ai's key competitors?
Some companies that are related to Renalytix Ai include Volpara Health Tech (VHT), Profound Medical (PRN), Akumin (AKU), Exagen (XGN), Senseonics (SENS), Palatin Technologies (PTN), Oncosil Medical (OSL), Yourgene Health (YGEN), MaxCyte (MXCT), Lexagene (LXG), BARD1 Life Sciences (BD1), Oncimmune (ONC), Sernova (SVA), GeneNews (GEN) and SQI Diagnostics (SQD).
Who are Renalytix Ai's key executives?
Renalytix Ai's management team includes the folowing people:
- Mr. James R. McCullough, CEO & Director (Age 51)
- Mr. O. James Sterling III, Chief Financial Officer
- Dr. Sally Bowden, Chief Operating Officer
- Fergus Fleming, CTO & Director
- Salim Hamir, Company Sec.
How do I buy shares of Renalytix Ai?
Shares of RENX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Renalytix Ai's stock price today?
One share of RENX stock can currently be purchased for approximately GBX 345.
How big of a company is Renalytix Ai?
What is Renalytix Ai's official website?
MarketBeat Community Rating for Renalytix Ai (LON RENX)
MarketBeat's community ratings are surveys of what our community members think about Renalytix Ai and other stocks. Vote "Outperform" if you believe RENX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RENX will underperform the S&P 500 over the long term. You may vote once every thirty days.
